Company: Q32 BioEvent type: Phase 2 clinical data and development prioritizationModality: Monoclonal antibody / immune pathway modulationAsset: BempikibartTarget: IL-7Rα, with blockade of IL-7 and TSLP signalingDisease area: Alopecia areataInsilens signal strength: 3 / 5 Summary Q32 Bio reported positive 36-week…
Company: Wave Life Sciences / Roche / IonisEvent type: Platform readthrough and competitive analysisModality: Antisense oligonucleotideAsset: WVE-003Disease area: Huntington’s diseaseInsilens signal strength: 3 / 5 Summary Roche’s discontinuation of tominersen in Huntington’s disease creates an important platform-level readthrough for Wave…
Company: Sanofi (EURONEXT: SAN; Nasdaq: SNY) Event Type: FDA approval — subcutaneous formulation, ahead of the July 23 PDUFA Modality: Anti-CD38 monoclonal antibody, subcutaneous — delivered via CirCLIQ on-body injector (Enable Injections enFuse platform) and manual SC Target: CD38 Indication:…
